Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARCT NASDAQ:NVCT NASDAQ:SGMT NYSE:VHAQ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARCTArcturus Therapeutics$8.41-1.9%$7.84$5.85▼$24.17$243.59M2.43342,463 shs443,360 shsNVCTNuvectis Pharma$9.71+9.2%$8.50$5.55▼$11.15$245.97M-0.1150,512 shs194,266 shsSGMTSagimet Biosciences$7.72-2.3%$5.73$3.08▼$11.41$257.42M3.63.25 million shs1.29 million shsVHAQViveon Health Acquisition$11.00$11.00$0.00▼$12.48$62.26M-0.112 shsN/AMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARCTArcturus Therapeutics-2.55%-5.19%+4.73%+14.73%-29.45%NVCTNuvectis Pharma+13.70%+11.74%+28.44%+14.78%+3.63%SGMTSagimet Biosciences+1.45%-11.77%+45.11%+26.97%+115.04%VHAQViveon Health Acquisition0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARCTArcturus Therapeutics$8.41-1.9%$7.84$5.85▼$24.17$243.59M2.43342,463 shs443,360 shsNVCTNuvectis Pharma$9.71+9.2%$8.50$5.55▼$11.15$245.97M-0.1150,512 shs194,266 shsSGMTSagimet Biosciences$7.72-2.3%$5.73$3.08▼$11.41$257.42M3.63.25 million shs1.29 million shsVHAQViveon Health Acquisition$11.00$11.00$0.00▼$12.48$62.26M-0.112 shsN/AMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARCTArcturus Therapeutics-2.55%-5.19%+4.73%+14.73%-29.45%NVCTNuvectis Pharma+13.70%+11.74%+28.44%+14.78%+3.63%SGMTSagimet Biosciences+1.45%-11.77%+45.11%+26.97%+115.04%VHAQViveon Health Acquisition0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARCTArcturus Therapeutics 2.69Moderate Buy$29.50250.77% UpsideNVCTNuvectis Pharma 2.00Hold$10.002.99% UpsideSGMTSagimet Biosciences 2.67Moderate Buy$28.63270.79% UpsideVHAQViveon Health Acquisition 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest VHAQ, SGMT, ARCT, and NVCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026SGMTSagimet Biosciences Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$28.00 ➝ $49.005/1/2026SGMTSagimet Biosciences OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform4/29/2026SGMTSagimet Biosciences GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$27.00 ➝ $25.004/21/2026ARCTArcturus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026SGMTSagimet Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/26/2026SGMTSagimet Biosciences Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$28.003/18/2026ARCTArcturus Therapeutics B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral ➝ Buy$22.003/17/2026ARCTArcturus Therapeutics B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy3/11/2026SGMTSagimet Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$29.003/5/2026ARCTArcturus Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$66.00 ➝ $21.003/4/2026ARCTArcturus Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$7.00 ➝ $8.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARCTArcturus Therapeutics$82.03M2.91N/AN/A$7.53 per share1.12NVCTNuvectis PharmaN/AN/AN/AN/A$0.72 per shareN/ASGMTSagimet Biosciences$2M125.76N/AN/A$3.42 per share2.26VHAQViveon Health AcquisitionN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARCTArcturus Therapeutics-$65.78M-$2.38N/AN/AN/A-80.19%-29.13%-22.03%5/7/2026 (Confirmed)NVCTNuvectis Pharma-$26.44M-$1.32N/AN/AN/AN/A-143.91%-92.79%N/ASGMTSagimet Biosciences-$51.04M-$1.57N/AN/AN/AN/A-40.85%-38.63%5/14/2026 (Estimated)VHAQViveon Health Acquisition-$610KN/AN/AN/AN/AN/AN/AN/AN/ALatest VHAQ, SGMT, ARCT, and NVCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026SGMTSagimet Biosciences-$0.3709N/AN/AN/AN/AN/A5/7/2026Q1 2026ARCTArcturus Therapeutics-$1.0133N/AN/AN/A$6.30 millionN/A5/5/2026Q1 2026NVCTNuvectis Pharma-$0.30-$0.26+$0.04-$0.26N/AN/A3/11/2026Q4 2025SGMTSagimet Biosciences-$0.43-$0.29+$0.14-$0.29N/AN/A3/3/2026Q4 2025ARCTArcturus Therapeutics-$0.92-$1.03-$0.11-$1.0230$14.32 million$7.20 million2/11/2026Q4 2025NVCTNuvectis Pharma-$0.26-$0.31-$0.05-$0.31N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARCTArcturus TherapeuticsN/AN/AN/AN/AN/ANVCTNuvectis PharmaN/AN/AN/AN/AN/ASGMTSagimet BiosciencesN/AN/AN/AN/AN/AVHAQViveon Health AcquisitionN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARCTArcturus TherapeuticsN/A6.646.64NVCTNuvectis PharmaN/A2.382.38SGMTSagimet BiosciencesN/A22.8222.82VHAQViveon Health AcquisitionN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARCTArcturus Therapeutics94.54%NVCTNuvectis Pharma96.77%SGMTSagimet Biosciences87.86%VHAQViveon Health Acquisition22.14%Insider OwnershipCompanyInsider OwnershipARCTArcturus Therapeutics17.80%NVCTNuvectis Pharma30.52%SGMTSagimet Biosciences14.70%VHAQViveon Health Acquisition75.27%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARCTArcturus Therapeutics18028.42 million23.36 millionOptionableNVCTNuvectis Pharma827.67 million19.22 millionNot OptionableSGMTSagimet Biosciences832.58 million27.80 millionOptionableVHAQViveon Health Acquisition25.66 million1.40 millionNot OptionableVHAQ, SGMT, ARCT, and NVCT HeadlinesRecent News About These CompaniesViveon Health Acquisition CorpNovember 21, 2024 | investing.comClearday, Inc. (CLRD)September 6, 2024 | finance.yahoo.comClearday Announces Board Resignation of Jeff Coleman with Warm Wishes for His Future Success - UpdatedMay 3, 2024 | finance.yahoo.comClearday Announces Board Resignation of Jeff Coleman with Warm Wishes for His Future SuccessMay 2, 2024 | finance.yahoo.comViveon Health Acquisition Corp.: Viveon Healthcare Acquisition Corp. Confirms Commitment To Proceed With Business Combination ProcessFebruary 28, 2024 | finanznachrichten.deVIVEON HEALTHCARE ACQUISITION CORP. CONFIRMS COMMITMENT TO PROCEED WITH BUSINESS COMBINATION PROCESSFebruary 27, 2024 | globenewswire.comNYSE American to Suspend Trading in Viveon Health Acquisition Corp. (VHAQ)February 21, 2024 | finance.yahoo.comViveon Health Acquisition Corp. Receives Commencement of Delisting Notice From the NYSEDecember 27, 2023 | finance.yahoo.comNYSE American to Commence Delisting Proceedings Against Viveon Health Acquisition Corp. (VHAQ)December 22, 2023 | tmcnet.comSan Antonio, Texas Clearday (CLRD-OTCQX) is proud to honor our US Veterans through the Company’s Clearday Club in San Antonio, Texas.November 13, 2023 | finance.yahoo.comNYSE American to Commence Delisting Proceedings with Respect to the Warrants of Viveon Health Acquisition Corp. (VHAQ.WS)October 24, 2023 | finance.yahoo.comVHAQ-R Viveon Health Acquisition Corp.September 23, 2023 | seekingalpha.comViveon Health Acquisition Received Audit Opinion With Going Concern ExplanationSeptember 15, 2023 | marketwatch.comVIVEON HEALTH ACQUISITION CORP. RECEIVED AUDIT OPINION WITH GOING CONCERN EXPLANATIONSeptember 15, 2023 | finance.yahoo.comViveon Healthcare Increases Consideration Offered to Clearday ShareholdersSeptember 5, 2023 | finance.yahoo.comSPAC Viveon ups merger consideration for Clearday to $500MAugust 29, 2023 | msn.comViveon Health Acquisition Corp. and Clearday, Inc. Announce Amendment to their Definitive Merger AgreementAugust 29, 2023 | finance.yahoo.comVIVEON HEALTH ACQUISITION CORP. RECEIVES NYSE NOTICE REGARDING DELAYED FORM 10-K FILINGApril 25, 2023 | finance.yahoo.comViveon Health Acquisition Corp. (VHAQ-RT)April 18, 2023 | finance.yahoo.com(Updated) Clearday Inc. and Viveon Health Acquisition Corp. Announce Definitive Merger Agreement to Accelerate Innovative Longevity-Tech Platform to MarketApril 12, 2023 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVHAQ, SGMT, ARCT, and NVCT Company DescriptionsArcturus Therapeutics NASDAQ:ARCT$8.41 -0.16 (-1.87%) Closing price 05/5/2026 04:00 PM EasternExtended Trading$8.35 -0.06 (-0.77%) As of 05/5/2026 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.Nuvectis Pharma NASDAQ:NVCT$9.71 +0.82 (+9.22%) Closing price 05/5/2026 04:00 PM EasternExtended Trading$9.51 -0.20 (-2.03%) As of 05/5/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.Sagimet Biosciences NASDAQ:SGMT$7.72 -0.18 (-2.28%) Closing price 05/5/2026 04:00 PM EasternExtended Trading$7.64 -0.08 (-0.97%) As of 05/5/2026 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.Viveon Health Acquisition NYSE:VHAQViveon Health Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses in the healthcare industry in North America. The company was incorporated in 2020 and is based in Atlanta, Georgia. Viveon Health Acquisition Corp. operates as a subsidiary of Viveon Health LLC. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom The Great Chip Divide: AI Chip War Pivots from Hype to Execution Atomic Dividends: Big Tech's New Energy Bet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
